Velvio

Executive Summary

Velvio is a privately held German biotech company founded in 2020, headquartered in Munich, dedicated to developing novel therapies that restore organ repair functions. Its pipeline targets two orphan indications: amyotrophic lateral sclerosis (ALS) and idiopathic pulmonary fibrosis (IPF), with a third program aimed at enhancing immune checkpoint inhibitor responses in solid tumors. The company’s lead ALS candidate is poised to enter first-in-human clinical trials, while the IPF program is completing preclinical in vivo development. Velvio leverages a proprietary platform focused on regenerative mechanisms, positioning it to address significant unmet needs in neurodegeneration, fibrosis, and immuno-oncology. At the pre-clinical stage, Velvio’s progress toward clinical translation represents a key inflection point, with potential value creation driven by upcoming regulatory filings and data readouts.

Upcoming Catalysts (preview)

• Q3 2026First-in-human clinical trial initiation for ALS70% success
• Q4 2026Completion of preclinical development and IND/CTA submission for IPF80% success
• Q4 2026Preclinical proof-of-concept data for immuno-oncology combination therapy60% success